Companion Diagnostics Market Projected to Reach $11.57 Billion by 2031

Demand for diagnostic precision is reshaping the healthcare landscape as pharmaceutical and biotechnology firms prioritize biomarker-based treatment models. In 2025, the sector was dominated by assays, kits, and reagents, which accounted for 67.3% of total market activity. Polymerase chain reaction (PCR) technology currently leads the diagnostic field due to its established regulatory standing and rapid processing capabilities. However, next-generation sequencing is anticipated to outpace traditional methods as genomic profiling becomes essential for managing complex diseases and rare genetic disorders.

Oncology remains the primary driver of this growth, reflecting the rising incidence of cancer and the subsequent need to identify patients most likely to respond to targeted immunotherapy. North America currently holds the largest regional share at 44.7%, supported by robust healthcare infrastructure and high levels of investment in molecular diagnostics. While Western markets maintain their lead, the Asia Pacific region is expected to accelerate its development through increased healthcare spending and a broader adoption of precision oncology tools. Major industry players, including F. Hoffmann-La Roche AG, Agilent Technologies, and Thermo Fisher Scientific, continue to influence the market through strategic partnerships and the expansion of their diagnostic portfolios.